UPCC 26417: A Phase 1/2a Open-label Study to Investigate the Safety and Tolerability Efficacy Pharmacokinetics and Immunogenicity of TAK-573 (formerly TEV-48573) Administered Intravenously as a Single Agent in Patients with Refractory Multiple Myeloma
Enrolling By Invitation
99 years or below
All
Phase
2
10 participants needed
1 Location
Brief description of study
Request for collaborative review: WIRB serving as IRB of record.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Multiple Myeloma
-
Age: 99 years or below
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 827714
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
